NYSE · Biotechnology

RCUS (RCUS) Stock

$28.19 -0.21% NYSE: RCUS Healthcare

Valuation

MetricValue
Price$28.19
Market Cap$3.55B
P/E Ratio-7.11
P/B Ratio3.73
P/S Ratio9.93
EPS (TTM)$-3.29
52-Week High$31.48
52-Week Low$7.91
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-55.94%
ROA-30.99%
ROCE-61.17%
Gross Margin-156.28%
Operating Margin-156.28%
Net Margin-1.56%
Debt/Equity0.19
Current Ratio4.36

Annual Financials (USD)

Metric20212022202320242025
Revenue$383.0M$112.0M$117.0M$258.0M$247.0M
Operating Profit$54.0M$-280.0M$-340.0M$-330.0M$-386.0M
Net Profit$53.0M$-267.0M$-307.0M$-283.0M$-353.0M
EPS$0.71$-3.71$-4.15$-3.14$-3.29
Op Margin14.1%-250.0%-290.6%-127.9%-156.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.6B$1.3B$1.1B$1.1B$1.1B
Total Liabilities$750.0M$688.0M$633.0M$665.0M$508.0M
Cash$148.0M$206.0M$127.0M$150.0M$222.0M
Borrowings$122.0M$120.0M$11.0M$60.0M$99.0M

Latest News

Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients Business Wire · Jul 22, 2026 Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer Business Wire · Jul 22, 2026 RCUS: Raising target price to $31.00 Argus Research · Jul 22, 2026 Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates Business Wire · Jul 21, 2026 An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run Motley Fool · Jul 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-256.0M$438.0M$-306.0M$-170.0M$-482.0M
Investing Cash Flow$-30.0M$-419.0M$170.0M$-90.0M$64.0M
Financing Cash Flow$12.0M$0$8.0M$2.0M$0
Net Cash Flow$-23.0M$58.0M$-79.0M$23.0M$72.0M
Free Cash Flow$-282.0M$432.0M$-330.0M$-176.0M$-484.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-20.87%
Quick Ratio4.04
Interest Coverage-48.25
Return 1Y224.56%
Return 3Y48.35%
Return 5Y-9.50%

Ownership

Insiders Held29.15%
Institutions Held72.62%
Institutions Float Held102.50%
Institutional HolderSharesReport Date
Gilead Sciences Inc31,424,7602026-03-31
Blackrock Inc.15,226,4752026-03-31
Wellington Management Group, LLP6,089,5162026-03-31
State Street Corporation5,412,9012026-03-31
Suvretta Capital Management, LLC5,030,9932026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AGIO $31.72 +0.38% -3.56 $1.89B 0.00%
BEAM $25.62 +2.19% -35.36 $2.64B 0.00%
COGT $42.27 -1.33% -34.70 $7.22B 0.00%
DNLI $24.42 +1.03% -6.20 $3.88B 0.00%
ETNB89bio, Inc. $14.84 +0.00% -12.82 $2.20B 0.00%

About RCUS

RCUS stock trades at $28.19 with a market capitalization of $3.55B. The stock is valued at a price-to-earnings (P/E) ratio of -7.11, price-to-book of 3.73, price-to-sales of 9.93. Over the past 52 weeks the stock has ranged between $7.91 and $31.48, and currently trades 10.5% below its 52-week high.

On profitability, RCUS generates a return on equity (ROE) of -55.94%, return on capital employed of -61.17%, an operating margin of -156.28%, a net profit margin of -1.56%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNYSE High ROE StocksAll stock screens
Run Stock Screener Investing Guides